抗体偶联药物在治疗老年癌症患者中的应用：真正的价值是什么？
Antibody-drug conjugates in treating older patients suffering from cancer: what is the real value?
机构信息
Pharmacy Unit, IRCCS San Raffaele Hospital, Milan, Italy.
Oncology Unit, Casa di cura Igea, Milan, Italy.
出版信息
Hum Vaccin Immunother. 2021 Dec 2;17(12):5575-5578. doi: 10.1080/21645515.2021.1999711.
Abstract
Immunotherapeutic drugs and target therapies have represented an epochal change in treating cancer patients. They represent an attractive option in oncologists' armamentarium, particularly if we consider the optimal balance between efficacy and toxicity. As a step forward, immuno- and target-therapies have merged intending to improve efficacy: antibody-drug conjugates ensure the perfect combination. They allow the delivery of large amounts of drugs to the target with a limited 'off-target' effect and a low rate of adverse events. These aspects could make immunoconjugates palatable as the first choice for fragile patients, but solid evidence does not exist on the use of these drugs in this population type, especially older people.
摘要
免疫治疗药物和靶向治疗药物代表了癌症患者治疗的一个划时代的变化。它们是肿瘤学家武器库中极具吸引力的选择，尤其是在考虑疗效和毒性之间的最佳平衡时。作为向前迈进的一步，免疫治疗和靶向治疗已经融合在一起，旨在提高疗效：抗体药物偶联物确保了完美的结合。它们允许将大量药物递送到靶标，同时具有有限的“脱靶”效应和低不良反应率。这些方面可能使免疫偶联物成为脆弱患者的首选，但在这类人群中，特别是老年人中，使用这些药物的确凿证据尚不存在。
相似文献
1
Antibody-drug conjugates in treating older patients suffering from cancer: what is the real value?抗体偶联药物在治疗老年癌症患者中的应用：真正的价值是什么？
Hum Vaccin Immunother. 2021 Dec 2;17(12):5575-5578. doi: 10.1080/21645515.2021.1999711.
2
Safety and Tolerability of Antibody-Drug Conjugates in Cancer.抗体药物偶联物在癌症中的安全性和耐受性。
Drug Saf. 2019 Feb;42(2):295-314. doi: 10.1007/s40264-018-0775-7.
3
Antibody-drug conjugates: the new generation of biotechnological therapies against cancer.抗体药物偶联物：新一代针对癌症的生物技术疗法。
Gac Med Mex. 2020;156(3):228-235. doi: 10.24875/GMM.M20000388.
4
Picking the optimal target for antibody-drug conjugates.选择抗体药物偶联物的最佳靶点。
Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e103.
5
Adverse events of antibody-drug conjugates on the ocular surface in cancer therapy.抗体药物偶联物在癌症治疗中对眼表面的不良反应。
Clin Transl Oncol. 2023 Nov;25(11):3086-3100. doi: 10.1007/s12094-023-03261-y. Epub 2023 Jul 15.
6
Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.抗体药物偶联物作为癌症治疗药物：过去、现在与未来
J Clin Pharmacol. 2017 Oct;57 Suppl 10:S11-S25. doi: 10.1002/jcph.981.
7
Predicting chemotherapy toxicity in older adults: Comparing the predictive value of the CARG Toxicity Score with oncologists' estimates of toxicity based on clinical judgement.预测老年人化疗毒性：比较 CARG 毒性评分与肿瘤学家基于临床判断估计毒性的预测价值。
J Geriatr Oncol. 2019 Mar;10(2):202-209. doi: 10.1016/j.jgo.2018.08.010. Epub 2018 Sep 14.
8
Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells.抗体药物偶联物：利用单克隆抗体将细胞毒性药物传递至癌细胞。
Ther Deliv. 2011 Mar;2(3):397-416. doi: 10.4155/tde.10.98.
9
Antibody-Drug Conjugates and Ocular Toxicity.抗体药物偶联物与眼部毒性
J Ocul Pharmacol Ther. 2023 Dec;39(10):675-691. doi: 10.1089/jop.2023.0069. Epub 2023 Aug 23.
10
Antibody drug conjugates under investigation in phase I and phase II clinical trials for gastrointestinal cancer.正在进行的 I 期和 II 期临床试验中用于胃肠道癌症的抗体药物偶联物。
Expert Opin Investig Drugs. 2018 Nov;27(11):901-916. doi: 10.1080/13543784.2018.1541085. Epub 2018 Nov 11.
引用本文的文献
1
Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice.用于治疗肺癌的药物偶联物：从药物发现到临床实践
Exp Hematol Oncol. 2024 Mar 1;13(1):26. doi: 10.1186/s40164-024-00493-8.
2
Antibody-drug conjugates come of age in oncology.抗体偶联药物在肿瘤学中崭露头角。
Nat Rev Drug Discov. 2023 Aug;22(8):641-661. doi: 10.1038/s41573-023-00709-2. Epub 2023 Jun 12.
本文引用的文献
1
Immunotherapy in Older Adults With Cancer.老年癌症患者的免疫治疗
J Clin Oncol. 2021 Jul 1;39(19):2115-2127. doi: 10.1200/JCO.21.00138. Epub 2021 May 27.
2
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.在铂类不耐受的晚期尿路上皮癌患者中，在使用PD-1或PD-L1抑制剂后使用恩杂鲁胺（EV‑201）：一项多中心、单臂、2期试验。
Lancet Oncol. 2021 Jun;22(6):872-882. doi: 10.1016/S1470-2045(21)00094-2. Epub 2021 May 12.
3
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.曲妥珠单抗-德鲁替康（DS-8201）治疗人表皮生长因子受体 2（HER2）表达的转移性结直肠癌（DESTINY-CRC01）患者：一项多中心、开放标签、Ⅱ期临床试验。
Lancet Oncol. 2021 Jun;22(6):779-789. doi: 10.1016/S1470-2045(21)00086-3. Epub 2021 May 4.
4
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.Sacituzumab Govitecan 治疗转移性三阴性乳腺癌。
N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485.
5
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.沙库巴曲单抗戈维替康，一种 Trop-2 导向的抗体药物偶联物，用于上皮癌患者：来自 IMMU-132-01 篮子试验的 I 期/II 期的最终安全性和疗效结果。
Ann Oncol. 2021 Jun;32(6):746-756. doi: 10.1016/j.annonc.2021.03.005. Epub 2021 Mar 16.
6
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.恩福妥单抗 Vedotin 治疗既往治疗的晚期尿路上皮癌。
N Engl J Med. 2021 Mar 25;384(12):1125-1135. doi: 10.1056/NEJMoa2035807. Epub 2021 Feb 12.
7
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.恩美曲妥珠单抗联合阿替利珠单抗对比恩美曲妥珠单抗联合安慰剂用于既往治疗、HER2 阳性晚期乳腺癌（KATE2）：一项 2 期、多中心、随机、双盲试验。
Lancet Oncol. 2020 Oct;21(10):1283-1295. doi: 10.1016/S1470-2045(20)30465-4.
8
Older adult participation in cancer clinical trials: A systematic review of barriers and interventions.老年人参与癌症临床试验：障碍和干预措施的系统评价。
CA Cancer J Clin. 2021 Jan;71(1):78-92. doi: 10.3322/caac.21638. Epub 2020 Oct 1.
9
Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial.在既往治疗的激素受体阳性/HER2 阴性转移性乳腺癌中应用 sacituzumab govitecan：一项 I/II 期、单臂、篮子试验的最终结果。
Ann Oncol. 2020 Dec;31(12):1709-1718. doi: 10.1016/j.annonc.2020.09.004. Epub 2020 Sep 15.
10
Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial.曲妥珠单抗-美坦新偶联物联合卡培他滨对比曲妥珠单抗-美坦新偶联物单药治疗既往治疗过的 ERBB2（HER2）阳性转移性乳腺癌患者的疗效和安全性：一项Ⅰ期和随机Ⅱ期试验。
JAMA Oncol. 2020 Aug 1;6(8):1203-1209. doi: 10.1001/jamaoncol.2020.1796.
Zotero 插件